Lung Cancer

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the role of liquid biopsies for patients with lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing challenges for patients with advanced lung cancer.

Combining pembrolizumab with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer.

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses disparities in the treatment of lung cancer.

Paul A. Bunn, Jr, MD, discusses the IMpower150 study and other immunotherapy combinations in NSCLC.

Results from a recent multicenter, retrospective analysis of 242 patients with advanced non–small cell lung cancer (NSCLC) found that 16% developed hyperprogression during anti–PD-1/PD-L1 treatment.

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of afatinib (Gilotrif) for the frontline treatment of patients with metastatic non

The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.

Lecia V. Sequist, MD, reflects on the practice-changing osimertinib data, ongoing trials exploring combination regimens, and discusses the potential for immunotherapy in EGFR-positive NSCLC.

Amid rapid-fire developments in non–small cell lung cancer (NSCLC) research, the role of checkpoint immunotherapy continues to mature.

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center, discusses chemotherapy in patients with non

Increasing evidence suggests that immune responses against SCLC cells make immunotherapy a rational approach.

Erminia Massarelli, MD, PhD, discusses the evolving paradigm of ALK-positive non-small cell lung cancer based on recent regulatory decisions and what additional advancements are expected in the year ahead.